Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mercuri

Showing results (241-250 of 259) with videos related to

Pageof 26
Sort By:
Journal of Inherited Metabolic Disease|September 11, 2019
Early neurodevelopmental characterization in children with cobalamin C/defectDaniela Ricci, Diego Martinelli, Gloria Ferrantini, et al.
JAMA|September 11, 1996
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trialN O Borhani, M Mercuri, P A Borhani, et al.
La Radiologia Medica|March 11, 2019
Value of structured reporting in neuromuscular disordersFrancesco Alessandrino, Lara Cristiano, Claudia Maria Cinnante, et al.
Current Medical Research and Opinion|July 24, 2001
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trialD R Illingworth, J R Crouse, D B Hunninghake, et al.
The American Journal of Cardiology|July 29, 2000
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levelsJ J Kastelein, J L Isaacsohn, L Ose, et al.
JAMA Neurology|May 12, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical TrialKrista Vandenborne, Glenn A Walter, Volker Straub, et al.
Clinical Cardiology|February 19, 2000
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study GroupL Ose, M H Davidson, E A Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2010
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocolS Ferrari, K Sundby Hall, R Luksch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremitiesP Picci, T Böhling, G Bacci, et al.
Nature Medicine|December 8, 2025
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Pageof 26

Showing results (241-250 of 259) with videos related to

Sort By:
Pageof 26
Journal of Inherited Metabolic Disease|September 11, 2019
Early neurodevelopmental characterization in children with cobalamin C/defectDaniela Ricci, Diego Martinelli, Gloria Ferrantini, et al.
JAMA|September 11, 1996
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trialN O Borhani, M Mercuri, P A Borhani, et al.
La Radiologia Medica|March 11, 2019
Value of structured reporting in neuromuscular disordersFrancesco Alessandrino, Lara Cristiano, Claudia Maria Cinnante, et al.
Current Medical Research and Opinion|July 24, 2001
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trialD R Illingworth, J R Crouse, D B Hunninghake, et al.
The American Journal of Cardiology|July 29, 2000
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levelsJ J Kastelein, J L Isaacsohn, L Ose, et al.
JAMA Neurology|May 12, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical TrialKrista Vandenborne, Glenn A Walter, Volker Straub, et al.
Clinical Cardiology|February 19, 2000
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study GroupL Ose, M H Davidson, E A Stein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2010
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocolS Ferrari, K Sundby Hall, R Luksch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremitiesP Picci, T Böhling, G Bacci, et al.
Nature Medicine|December 8, 2025
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Pageof 26